Literature DB >> 24239560

The role of cannabinoid 1 receptor expressing interneurons in behavior.

Jacquelyn A Brown1, Szatmár Horváth2, Krassimira A Garbett1, Martin J Schmidt3, Monika Everheart1, Levente Gellért4, Philip Ebert1, Károly Mirnics5.   

Abstract

Schizophrenia is a devastating neurodevelopmental disorder that affects approximately 1% of the population. Reduced expression of the 67-kDa protein isoform of glutamic acid decarboxylase (GAD67) is a hallmark of the disease and is encoded by the GAD1 gene. In schizophrenia, GAD67 downregulation occurs in multiple interneuronal subpopulations, including the cannabinoid receptor type 1 positive (CNR1+) cells, but the functional consequences of these disturbances are not well understood. To investigate the role of the CNR1-positive GABA-ergic interneurons in behavioral and molecular processes, we employed a novel, miRNA-mediated transgenic mouse approach. We silenced the Gad1 transcript using a miRNA engineered to specifically target Gad1 mRNA under the control of Cnr1 bacterial artificial chromosome. Behavioral characterization of our transgenic mice showed elevated and persistent conditioned fear associated with an auditory cue and a significantly altered response to an amphetamine challenge. These deficits could not be attributed to sensory deficits or changes in baseline learning and memory. Furthermore, HPLC analyses revealed that Cnr1/Gad1 mice have enhanced serotonin levels, but not dopamine levels in response to amphetamine. Our findings demonstrate that dysfunction of a small subset of interneurons can have a profound effect on behavior and that the GABA-ergic, monoamine, and cannabinoid systems are functionally interconnected. The results also suggest that understanding the function of various interneuronal subclasses might be essential to develop knowledge-based treatment strategies for various mental disorders including schizophrenia and substance abuse.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Amphetamine; Behavior; Cnr1; Dopamine; GAD67; Gad1; Interneuron; Schizophrenia; Serotonin; Transgenic; miRNA

Mesh:

Substances:

Year:  2013        PMID: 24239560      PMCID: PMC3946968          DOI: 10.1016/j.nbd.2013.11.001

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  83 in total

1.  Differential contribution of amygdala and hippocampus to cued and contextual fear conditioning.

Authors:  R G Phillips; J E LeDoux
Journal:  Behav Neurosci       Date:  1992-04       Impact factor: 1.912

2.  Molecular composition of the endocannabinoid system at glutamatergic synapses.

Authors:  István Katona; Gabriella M Urbán; Matthew Wallace; Catherine Ledent; Kwang-Mook Jung; Daniele Piomelli; Ken Mackie; Tamás F Freund
Journal:  J Neurosci       Date:  2006-05-24       Impact factor: 6.167

3.  The NIMH-MATRICS consensus statement on negative symptoms.

Authors:  Brian Kirkpatrick; Wayne S Fenton; William T Carpenter; Stephen R Marder
Journal:  Schizophr Bull       Date:  2006-02-15       Impact factor: 9.306

Review 4.  The role of serotonin in schizophrenia.

Authors:  N Iqbal; H M van Praag
Journal:  Eur Neuropsychopharmacol       Date:  1995       Impact factor: 4.600

5.  Relationship of cannabinoid CB1 receptor and cholecystokinin immunoreactivity in monkey dorsolateral prefrontal cortex.

Authors:  S M Eggan; D S Melchitzky; S R Sesack; K N Fish; D A Lewis
Journal:  Neuroscience       Date:  2010-06-11       Impact factor: 3.590

Review 6.  A neurobiological basis of social attachment.

Authors:  T R Insel
Journal:  Am J Psychiatry       Date:  1997-06       Impact factor: 18.112

7.  The CB receptor agonist WIN 55,212-2 fails to elicit disruption of prepulse inhibition of the startle in Sprague-Dawley rats.

Authors:  Marco Bortolato; Gian Nicola Aru; Roberto Frau; Marco Orrù; Grant Christopher Luckey; Gianluca Boi; Gian Luigi Gessa
Journal:  Psychopharmacology (Berl)       Date:  2004-07-28       Impact factor: 4.530

8.  Substance use in severe mental illness: self-medication and vulnerability factors.

Authors:  Jacopo Vittoriano Bizzarri; Paola Rucci; Alfredo Sbrana; Mario Miniati; Federica Raimondi; Laura Ravani; Guido Jacopo Massei; Francesca Milani; Marta Milianti; Gabriele Massei; Chiara Gonnelli; Giovanni Battista Cassano
Journal:  Psychiatry Res       Date:  2008-12-02       Impact factor: 3.222

9.  Prevalence and stability of social skill deficits in schizophrenia.

Authors:  K T Mueser; A S Bellack; M S Douglas; R L Morrison
Journal:  Schizophr Res       Date:  1991-09       Impact factor: 4.939

10.  The acute effects of synthetic intravenous Delta9-tetrahydrocannabinol on psychosis, mood and cognitive functioning.

Authors:  P D Morrison; V Zois; D A McKeown; T D Lee; D W Holt; J F Powell; S Kapur; R M Murray
Journal:  Psychol Med       Date:  2009-04-01       Impact factor: 7.723

View more
  14 in total

Review 1.  Neurodevelopment, GABA system dysfunction, and schizophrenia.

Authors:  Martin J Schmidt; Karoly Mirnics
Journal:  Neuropsychopharmacology       Date:  2014-04-24       Impact factor: 7.853

2.  Cortical Gene Expression After a Conditional Knockout of 67 kDa Glutamic Acid Decarboxylase in Parvalbumin Neurons.

Authors:  Danko Georgiev; Toru Yoshihara; Rika Kawabata; Takurou Matsubara; Makoto Tsubomoto; Yoshio Minabe; David A Lewis; Takanori Hashimoto
Journal:  Schizophr Bull       Date:  2016-03-15       Impact factor: 9.306

3.  What Gene Mutations Affect Serotonin in Mice?

Authors:  Richard C Tenpenny; Kathryn G Commons
Journal:  ACS Chem Neurosci       Date:  2017-04-27       Impact factor: 4.418

Review 4.  Neuropeptide System Regulation of Prefrontal Cortex Circuitry: Implications for Neuropsychiatric Disorders.

Authors:  Sanne M Casello; Rodolfo J Flores; Hector E Yarur; Huikun Wang; Monique Awanyai; Miguel A Arenivar; Rosario B Jaime-Lara; Hector Bravo-Rivera; Hugo A Tejeda
Journal:  Front Neural Circuits       Date:  2022-06-21       Impact factor: 3.342

Review 5.  Endogenous cannabinoid signaling at inhibitory interneurons.

Authors:  Thomas J Younts; Pablo E Castillo
Journal:  Curr Opin Neurobiol       Date:  2013-12-28       Impact factor: 6.627

Review 6.  The Role of Endocannabinoid Signaling in Cortical Inhibitory Neuron Dysfunction in Schizophrenia.

Authors:  David W Volk; David A Lewis
Journal:  Biol Psychiatry       Date:  2015-06-19       Impact factor: 13.382

7.  Disruption of social cognition in the sub-chronic PCP rat model of schizophrenia: Possible involvement of the endocannabinoid system.

Authors:  Alexandre Seillier; Andrea Giuffrida
Journal:  Eur Neuropsychopharmacol       Date:  2015-12-10       Impact factor: 4.600

8.  Inhibition of parvalbumin-expressing interneurons results in complex behavioral changes.

Authors:  J A Brown; T S Ramikie; M J Schmidt; R Báldi; K Garbett; M G Everheart; L E Warren; L Gellért; S Horváth; S Patel; Károly Mirnics
Journal:  Mol Psychiatry       Date:  2015-01-27       Impact factor: 15.992

9.  Bridging the Gap between Genes and Language Deficits in Schizophrenia: An Oscillopathic Approach.

Authors:  Elliot Murphy; Antonio Benítez-Burraco
Journal:  Front Hum Neurosci       Date:  2016-08-23       Impact factor: 3.169

10.  Comparative density of CCK- and PV-GABA cells within the cortex and hippocampus.

Authors:  Paul D Whissell; Janine D Cajanding; Nicole Fogel; Jun Chul Kim
Journal:  Front Neuroanat       Date:  2015-09-23       Impact factor: 3.856

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.